Determinants of postchemotherapy nausea and vomiting in patients with cancer

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 116-123

  Osoba, D ^a   Zee, B ^a   Pater, J ^a   Warr, D ^a   Latreille, J ^a   Kaizer, L ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; BEHAVIOR MODIFICATION; CANCER CHEMOTHERAPY; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SCORING SYSTEM; SELF REPORT; VOMITING;

EID: 0031032566     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.116     Document Type: Article

References (25)

1. Perez EA: Review of the preclinical pharmacology and the comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036-1043, 1995
2. Osoba D, Warr DG, Fitch MI, et al: Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: A consensus. Can J Oncol 5:381-400, 1995
3. Kaizer L, Warr D, Hoskins P, et al: The effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050-1057, 1994
4. Warr D, Willan AR, Fine S, et al: A double-blind comparison of granisetron with dexamethasone plus prochlorperazine for the prevention of nausea and emesis due to moderately emetogenic chemotherapy. J Natl Cancer Inst 83:1169-1173, 1991
5. Latreille J, Stewart D, Laberge F, et al: Dexamethasone improves the efficacy of granisetron in the first 24h following high-dose cisplatin chemotherapy. Support Care Cancer 3:307-312, 1995
6. Johnston D, Latreille J, Laberge F, et al: Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP). A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Proc Am Soc Clin Oncol 14:529, 1995 (abstr 1745)
7. Kris MG, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114, 1989
8. Gralla RJ, Tyson LB, Dris MG, et al: The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 71:289-301, 1987
9. Cohen RE, Blanchard EB, Ruckdeschel JC, et al: Prevalence and correlates of posttreatment and anticipatory nausea and vomiting in cancer chemotherapy. J Psychosom Res 30:643-654, 1986
10. Olver N, Simon R, Aisner J: Antiemetic studies: A methodological discussion. Cancer Treat Rep 70:555-563, 1986
11. Sullivan JR, Leyden MJ, Bell R: Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309:796, 1983
12. Roila F, Tonato M, Basurto C, et al: Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients. A randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5:141-149, 1987
13. Parikh PM, Charak BS, Banavali SD, et al: A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin. Cancer 62:2263-2266, 1988
14. Pollera CF, Giannarelli D: Prognostic factors influencing cisplatin-induced emesis. Cancer 64:1117-1122, 1989
15. Pater J, Slamet L, Zee B, et al: Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer 2:161-166, 1994
16. Jacobsen PB, Bovbjerg DH, Redd WH: Anticipatory anxiety in women receiving chemotherapy for breast cancer. Health Psychol 12:469-475, 1993
17. Morrow GR: Behavioural factors influencing the development and expression of chemotherapy induced side effects. Br J Cancer 19:S54-S61, 1992 (suppl)
18. Aaronson N, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365-376, 1993
19. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
20. Willan AR, Warr D, Pater JL, et al: Methodological issues and antiemetic studies, in Osoba D (ed): Effect of Cancer on Quality of Life. Boca Raton, FL, CRC Press, 1991, pp 229-249
21. Fetting JH, Grochow LB, Folstein MF, et al: The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487-1493, 1982
22. Milliken GA, Johnson DE: Analysis of Messy Data. Volume I: Designed Experiments. New York, NY, Van Nostrand Rheinhold, 1984
23. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989
24. Morrow GR, Hickok JT: Behavioural treatment of chemotherapy-induced nausea and vomiting. Oncology 7:83-89, 1993
25. Burish TG, Tope DM: Psychological technique for controlling the adverse side effects of cancer chemotherapy: Findings from a decade of research. J Pain Symptom Manage 7:287-301, 1992